Core Insights - GT Biopharma, Inc. is a clinical stage immuno-oncology company focused on developing therapeutics based on its proprietary TriKE NK cell engager platform [1][4] - Dr. Jeffrey Miller from the University of Minnesota will present at the 10th Anniversary of the Innate Killer Summit, discussing the advantages of tri-specific engagers in enhancing NK cell activity [2] Company Developments - GTB-3650, a second-generation TriKE, is currently in a Phase 1 dose escalation study for patients with hematological malignancies, with enrollment proceeding as expected [3] - The study will evaluate GTB-3650 in approximately 14 patients with relapsed or refractory CD33 expressing hematologic malignancies, including refractory acute myeloid leukemia and high-risk myelodysplastic syndrome [3] - Initial data from the GTB-3650 study is anticipated to be shared in 2025 [3] Technology and Collaboration - The TriKE platform is designed to enhance the cancer-killing abilities of natural killer cells in patients [4] - GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to develop and commercialize therapies using TriKE technology [4]